CCO Treatment Updates
Advances in the Treatment of Lymphoproliferative Malignancies: Promising Directions in Mantle Cell Lymphoma, Follicular Lymphoma, and Waldenstrom’s Macroglobulinemia
Mantle Cell Lymphoma: State of the Art |
Module 1 of 4 |
|
CME Program Director: James O. Armitage, MD
|
|
Andre Goy, MD, reviews current clinical data regarding treatment of patients with mantle cell lymphoma.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Define the diagnosis of mantle cell lymphoma
- Discuss the use of rituximab alone and in combination for the treatment of mantle cell lymphoma
- Review the use of radioimmunotherapy in the treatment of patients with mantle cell lymphoma
- Explain proteasome inhibition in the setting of mantle cell lymphoma treatment
|
The Evolving Role of Transplantation in Lymphoproliferative Malignancies |
Module 2 of 4 |
|
CME Program Director: James O. Armitage, MD
|
|
John P. Leonard, MD, reviews the use of stem-cell transplantation in the treatment of patients with Waldenström’s macroglobulinemia, follicular lymphoma, and mantle cell lymphoma.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Review the use of stem cell transplantation in the treatment of patients with Waldenström’s macroglobulinemia
- Discuss the differences between allogeneic and autologous stem cell transplantation in the treatment of patients with follicular and mantle cell lymphoma
- Explain the use of stem cell transplantation in combination with other therapeutic modalities for the treatment of lymphoma
|
Follicular Lymphoma: State of the Art |
Module 3 of 4 |
|
CME Program Director: James O. Armitage, MD
- Owen A. O'Connor, MD, PhD
|
|
|
Owen A. O’Connor, MD, PhD, reviews current clinical trial data regarding the treatment of patients with follicular lymphoma.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Articulate the various lymphoma classification schemes
- Recall the use of rituximab in the treatment of follicular lymphoma
- List novel compounds of interest in the treatment of follicular non-Hodgkin’s lymphoma
|
Novel Therapies for Waldenstrom’s Macroglobulinemia |
Module 4 of 4 |
|
CME Program Director: James O. Armitage, MD
- Steven P. Treon, MD, MA, PhD
|
|
|
Steven P. Treon, MD, MA, PhD, reviews current clinical trial data regarding the treatment of patients with Waldenström’s macroglobulinemia.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe recommended agents for the first-line treatment of Waldenström’s macroglobulinemia
- Discuss the use of immunomodulatory drugs in the treatment of Waldenström’s macroglobulinemia
- Identify targeted agents used to treat Waldenström’s macroglobulinemia
|
CCO Slidesets
Mantle Cell Lymphoma: State of the Art
 |
|
Format: Microsoft PowerPoint (.ppt) |
File size: 1.26 MB
|
The Evolving Role of Transplantation in Lymphoproliferative Malignancies
 |
|
Format: Microsoft PowerPoint (.ppt) |
File size: 536 KB
|
Follicular Lymphoma: State of the Art
 |
|
Format: Microsoft PowerPoint (.ppt) |
File size: 1.27 MB
|
Novel Therapies of Waldenstrom’s Macroglobulinemia
 |
|
Format: Microsoft PowerPoint (.ppt) |
File size: 583 KB
|
Disclaimer: The materials published on the Clinical Care Options
Web site reflect the views of the reviewers or authors of the
CCO
material, not those of Clinical Care Options, LLC, the CME provider,
or the companies providing educational grants. The materials may
discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
healthcare professional should be consulted before using any therapeutic
product discussed. Readers should verify all information and data before
treating patients or using any therapies described in these materials.
|
Jointly sponsored by University of Nebraska Medical Center, Center for Continuing Education and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
|